公开(公告)号：US09034338B2

公开(公告)日：2015-05-19

申请号：US12601974

申请日：2008-05-30

申请人： Yamila Carpio Gonzalez ,  Mario Pablo Estrada Garcia

发明人： Yamila Carpio Gonzalez ,  Mario Pablo Estrada Garcia

IPC分类号： A61K39/395 ,  A61K39/00 ,  A61K39/38 ,  C07K1/00 ,  C07K14/00 ,  C07K17/00 ,  C07H21/02 ,  C07H21/04 ,  C07K14/435 ,  A23K1/18 ,  A61K38/00

CPC分类号： A61K39/0003 ,  A23K50/80 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/552 ,  C07K14/43509 ,  C07K2319/00

摘要： The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a vaccine formulation as a purified protein and/or naked DNA, to induce an immune response in aquatic organisms against different ectoparasite species, including the known as sea lice, and pathogens associated with these infestations. The vaccine preparations, administered by oral route, immersion bath or injection, demonstrated its efficacy by producing IgM humoral immune response and reducing the number of parasites per fish in the vaccinated fishes.

公开(公告)号：US08741848B2

公开(公告)日：2014-06-03

申请号：US12162505

申请日：2007-01-29

申请人： Vivian Maria Sáez Martinez ,  Rolando Páez Meireles ,  Jorge Amador Berlanga Acosta ,  Blas Yamir Betancourt Rodriguez ,  José Ángel Ramón Hernández

发明人： Vivian Maria Sáez Martinez ,  Rolando Páez Meireles ,  Jorge Amador Berlanga Acosta ,  Blas Yamir Betancourt Rodriguez ,  José Ángel Ramón Hernández

IPC分类号： A61K38/00

CPC分类号： A61K9/1647 ,  A61K9/0021 ,  A61K38/1808

摘要： The present invention relates to a pharmaceutical composition that comprises polymeric microspheres containing epidermal growth factor (EGF) for the application, by the parenteral route, into the lower limbs of diabetic patients with cutaneous chronic ischemic ulcerative wounds. The pharmaceutical composition described herein, in contrast with the state of the art, is useful because reduce the administration frequency during the treatment and allows for the healing of the ulcerative wounds in a shorter time interval with respect to the injection of equivalent quantities of non-encapsulated EGF.

摘要翻译： 本发明涉及一种药物组合物，其包含含有表皮生长因子（EGF）的聚合微球，其通过肠胃外途径施用于具有皮肤慢性缺血性溃疡性创伤的糖尿病患者的下肢。 与现有技术相比，本文所述的药物组合物是有用的，因为在治疗期间减少施用频率并且允许在相对于注射等量的非 - 非甾体抗炎药物的较短时间间隔内愈合溃疡性伤口， 封装的EGF。

公开(公告)号：US08569470B2

公开(公告)日：2013-10-29

申请号：US12739658

申请日：2008-10-17

申请人： Diógenes Quintana Vázquez ,  Tamara Menendez Medina ,  Anabel Álvarez Acosta ,  Yoelys Cruz Leal ,  Gerardo Enrique Guillen Nieto

发明人： Diógenes Quintana Vázquez ,  Tamara Menendez Medina ,  Anabel Álvarez Acosta ,  Yoelys Cruz Leal ,  Gerardo Enrique Guillen Nieto

IPC分类号： C07H21/04 ,  A61K39/10

CPC分类号： G01N33/56911 ,  A61K39/00 ,  A61K39/099 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/53 ,  C07K14/235 ,  Y02A50/466

摘要： The present invention is related with the field of Biomedicine. It comprises the engineering of the Pertactin protein (Prn) and using it as part of bacterial vaccines, and more precisely, as part of acellular vaccines against Bordetella pertusis. The engineered Prn molecules comprise on their structure polimorfisms from different B. pertussis strains, and induce immune responses with protective capacity and opsonophagocytic activity when assayed as vaccines, higher than that generated by other pre-existing vaccines. The engineered Prn variants of the present invention are applicable in human and veterinary medicine.

摘要翻译： 本发明涉及生物医学领域。 它包括Pertactin蛋白（Prn）的工程，并将其用作细菌疫苗的一部分，更确切地说，它是作为针对博德氏菌的无细胞疫苗的一部分。 工程化的Prn分子在其结构上包括来自不同的百日咳杆菌菌株的结构，并且当测定为疫苗时诱导具有保护能力和调理吞噬活性的免疫应答，高于其他预先存在的疫苗产生的疫苗。 本发明的工程化Prn变体可应用于人兽药。

公开(公告)号：US08450559B2

公开(公告)日：2013-05-28

申请号：US12934685

申请日：2009-03-27

申请人： Orlando Borrás Hidalgo ,  Roxana Caridad Portieles Álvarez ,  Merardo Pujol Ferrer ,  Gil Alberto Enriquez Obregón ,  Ernesto Manuel González Ramos ,  Camilo Ayra Pardo ,  Carlos Guillermo Borroto Nordelo

发明人： Orlando Borrás Hidalgo ,  Roxana Caridad Portieles Álvarez ,  Merardo Pujol Ferrer ,  Gil Alberto Enriquez Obregón ,  Ernesto Manuel González Ramos ,  Camilo Ayra Pardo ,  Carlos Guillermo Borroto Nordelo

IPC分类号： A01H5/00 ,  C12N15/09 ,  C12N15/29 ,  C12N15/82

CPC分类号： A01N37/18 ,  C07K14/415 ,  C12N15/8279 ,  C12N15/8282

摘要： The present invention reveals a nucleic acid sequence from Nicotiana megalosiphon encoding for an anti-pathogenic protein. The invention comprises the use of this nucleic acid molecule in transgenic plants of agricultural interest to confer resistance to pathogens. The invention also includes a bioproduct that comprises this anti-pathogenic protein to control plant pathogen agents.

公开(公告)号：US07361638B2

公开(公告)日：2008-04-22

申请号：US10220750

申请日：2001-12-17

申请人： Jorge Berlanga Acosta ,  Gerardo Enrique Guillen Nieto ,  Diana Garcia Del Barco Herrera ,  Julio Raul Fernandez Masso ,  Mario Pablo Estrada Garcia ,  Isabel Guillen Perez ,  Jose Suarez Alba ,  Rebeca Martinez Rodriguez

发明人： Jorge Berlanga Acosta ,  Gerardo Enrique Guillen Nieto ,  Diana Garcia Del Barco Herrera ,  Julio Raul Fernandez Masso ,  Mario Pablo Estrada Garcia ,  Isabel Guillen Perez ,  Jose Suarez Alba ,  Rebeca Martinez Rodriguez

IPC分类号： A61K38/08 ,  A61K38/18 ,  C07K14/485 ,  C07K14/495

CPC分类号： A61K38/1841 ,  A61K38/08 ,  A61K38/1808 ,  A61K38/25 ,  A61K38/27 ,  A61K2300/00

摘要： This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use in preventing tissue damage due to blood flow suppression by enhancing tissue repair following ischemic damage. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is also useful in promoting cellular survival when tissue or organs are exposed to prolonged ischemic periods. The combination is useful as a prophylactic agent in those subjects prone to multiple organ failure (MOF) such as burn victims, multiple trauma patients, hypoxic neonates, acute respiratory distress syndrome patients, and necrotizing enterocolitis patients.

摘要翻译： 本发明涉及用于人的药物，特别涉及包含表皮生长因子（EGF）和生长激素促分泌素六肽（GHRP）的药物组合，用于通过增强缺血性损伤后的组织修复来预防由于血流抑制引起的组织损伤。 上述组合可以作为单一药物组合物使用。 或者，个体也可以以单独的方式接受EGF和GHRP，但是在单一治疗方案内，以便当器官在关键时间段内遭受血流剥夺时增强细胞存活。 这种组合减弱活性氧（ROS）形成及其相关的细胞毒性。 当组织或器官暴露于长时间缺血期时，它也可促进细胞存活。 该组合在易受多器官功能衰竭（MOF）的受试者，如烧伤受试者，多发性创伤患者，缺氧新生儿，急性呼吸窘迫综合征患者和坏死性小肠结肠炎患者中的预防剂是有用的。

公开(公告)号：US07318927B2

公开(公告)日：2008-01-15

申请号：US10469256

申请日：2002-02-22

申请人： Enrique Iglesias Perez ,  Dania M. Vazquez Blomquist ,  Carlos A. Duarte Cano

发明人： Enrique Iglesias Perez ,  Dania M. Vazquez Blomquist ,  Carlos A. Duarte Cano

IPC分类号： A61K39/21

CPC分类号： C07K14/005 ,  A61K2039/525 ,  C12N15/86 ,  C12N2740/16122 ,  C12N2740/16322

摘要： The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.

公开(公告)号：US20070141081A1

公开(公告)日：2007-06-21

申请号：US11705696

申请日：2007-02-13

申请人： Lisset Cruz ,  Rayner Diaz ,  Laura Vazquez ,  Aida Morales ,  Carlos Abarrategui ,  Iris Prado ,  Ricardo Silva Rodriguez ,  Glay Santiago ,  Gerardo Guillen Nieto ,  Maria Guzman Tirado ,  Beatriz de la Sierra Vazquez ,  Raul Espinosa Perez

发明人： Lisset Cruz ,  Rayner Diaz ,  Laura Vazquez ,  Aida Morales ,  Carlos Abarrategui ,  Iris Prado ,  Ricardo Silva Rodriguez ,  Glay Santiago ,  Gerardo Guillen Nieto ,  Maria Guzman Tirado ,  Beatriz de la Sierra Vazquez ,  Raul Espinosa Perez

IPC分类号： C12P19/34 ,  A61K39/12

CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K2319/00 ,  C12N9/0006 ,  C12N2770/24122 ,  Y02A50/386

摘要： The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.

摘要翻译： 本发明涉及获得编码蛋白质的蛋白质的嵌合链，其能够在受体中诱导抗登革病毒感染的血清型特异性和保护性体液免疫应答，从而消除血清型非特异性病毒免疫增强的作用 导致这种病理描述的出血和临床并发症。 核酸的这些嵌合链由来自脑膜炎奈瑟氏球菌与脱氢酶活性的突变蛋白质的基因的片段的特异性组合和编入来自登革病毒的包膜（E）蛋白的区域的片段组成，当插入时 表达载体，产生具有特定性质的嵌合蛋白。 所得到的本发明的嵌合分子适用于获得用于人类的疫苗制剂和高血清型特异性的诊断方法的制药工业。

公开(公告)号：US20060277628A1

公开(公告)日：2006-12-07

申请号：US10539476

申请日：2003-12-19

申请人： Guillermo Sosa ,  Alberto Radriguez ,  Daymi Remedios ,  Osmany Gonzalez

发明人： Guillermo Sosa ,  Alberto Radriguez ,  Daymi Remedios ,  Osmany Gonzalez

IPC分类号： A01H5/00 ,  A01H1/00 ,  C12N15/82 ,  C12N5/04

CPC分类号： C12N15/8216

摘要： An artificial promoter characterized for been a chimerical recombinant DNA molecule such that, when introduced in any class of plant cells, promotes high expression levels of any DNA molecule fused to its 3′ end. The basic genetic elements of the molecule described here are: a core promoter with a consensus TATA box, followed by an Exon/Intron/Exon region and a translation enhancer element, all of them artificially constructed. Transcription regulatory elements can be inserted upstream of the promoter here described to confer temporal-, organ- or tissue-specificity to the expression. The designed artificial genetic elements can be functionally inserted between any promoter active in plant cells and any DNA sequence to increase its transcription/translation levels.

摘要翻译： 一种人工启动子，其特征在于是嵌合重组DNA分子，使得当引入任何类别的植物细胞时，促进与其3'末端融合的任何DNA分子的高表达水平。 本文描述的分子的基本遗传元件是：具有共有TATA盒的核心启动子，其后是外显子/内含子/外显子区域和翻译增强子元件，所有这些都是人为构建的。 转录调节元件可以插入在这里描述的启动子的上游，以赋予表达的时间，组织或组织特异性。 设计的人造遗传元件可以功能性地插入到任何在植物细胞中活化的启动子和任何DNA序列之间以增加其转录/翻译水平。

公开(公告)号：US5286484A

公开(公告)日：1994-02-15

申请号：US754918

申请日：1991-09-05

申请人： Silva Rodriquez ,  Selman H. Sosa ,  Guillen Nieto ,  Saturnino H. Martinez ,  Julio R. F. Maso ,  Lidia I. N. Perez ,  Juan M. Grillo ,  Vivian M. Cordova ,  Sonia G. Blanco ,  Beatriz T. Santos ,  Jesus A. del Valle Rosales ,  Evelin C. Menendez ,  Anabel A. Acosta ,  Edelgis C. Rodriquez ,  Silian C. Leon ,  Alexis M. Lasa

发明人： Silva Rodriquez ,  Selman H. Sosa ,  Guillen Nieto ,  Saturnino H. Martinez ,  Julio R. F. Maso ,  Lidia I. N. Perez ,  Juan M. Grillo ,  Vivian M. Cordova ,  Sonia G. Blanco ,  Beatriz T. Santos ,  Jesus A. del Valle Rosales ,  Evelin C. Menendez ,  Anabel A. Acosta ,  Edelgis C. Rodriquez ,  Silian C. Leon ,  Alexis M. Lasa

IPC分类号： A61K39/095 ,  A61K39/00 ,  A61K39/395 ,  A61P31/04 ,  C07K14/00 ,  C07K14/195 ,  C07K14/22 ,  C07K14/41 ,  C07K16/00 ,  C07K16/12 ,  C07K16/40 ,  C07K19/00 ,  C12N1/21 ,  C12N9/02 ,  C12N9/10 ,  C12N15/00 ,  C12N15/09 ,  C12N15/31 ,  C12N15/53 ,  C12N15/54 ,  C12N15/70 ,  C12P21/02 ,  C12P21/08 ,  C12R1/19 ,  A61K39/02 ,  C07H15/12 ,  C12P21/06

CPC分类号： C12Y108/01004 ,  C07K14/22 ,  C07K16/1217 ,  C07K16/40 ,  C12N9/0051 ,  C12N9/1029 ,  A61K39/00 ,  C07K2319/00 ,  C07K2319/035 ,  C07K2319/40

摘要： The present invention is concerned with a method for the isolation of a nucleotide sequence which codes for a protein having a molecular weight of about 64,000 daltons, which is located on the outer membrane of N. meningitidis, as well as with the recombinant DNA obtained therefrom, which is used for the transformation of a host microorganism. The technical object pursued with the invention is the identification of a nucleotide sequence coding for a highly conserved and common protein for the majority of pathogenic Neisseria strains, the production of this protein with a high level of purity and in commercially useful amounts using the recombinant way, so that it can be used in diagnostic methods and vaccine preparations with a broad immunoprotection spectrum.

摘要翻译： 本发明涉及一种分离编码分子量约64,000道尔顿的蛋白质的核苷酸序列的方法，其位于脑膜炎奈瑟氏球菌的外膜上，以及由其获得的重组DNA ，其用于宿主微生物的转化。 本发明追求的技术目标是鉴定编码大多数致病性奈瑟氏球菌菌株的高度保守和常见蛋白质的核苷酸序列，使用重组方法产生具有高水平纯度和商业上有用量的该蛋白质 ，因此可用于具有广泛的免疫保护谱的诊断方法和疫苗制剂中。

公开(公告)号：US10434137B2

公开(公告)日：2019-10-08

申请号：US14943106

申请日：2015-11-17

申请人： Centro De Ingeniería Genetica Y Biotecnología

发明人： Celia Berta Fernandez Ortega ,  Anna Caridys Ramírez Suarez ,  Dionne Casillas Casanova ,  Taimi Emelia Paneque Guerrero ,  Raimundo Ubieta Gomez ,  Marta Dubed Echevarria ,  Leonor Margarita Navea Leyva ,  Lila Rosa Castellanos Serra ,  Carlos Antonio Duarte Cano ,  Viviana Falcon Cama ,  Osvaldo Reyes Acosta

IPC分类号： C12N15/113 ,  A61K38/10 ,  A61K31/5575 ,  A61K31/7105 ,  C07K14/47 ,  A61K31/19 ,  A61K31/713 ,  A61K38/17 ,  A61K45/06 ,  C12N5/0783

摘要： The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the the proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, including peptides and/or interfering RNA and/or lipidic compounds, the agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection.